Protein Z plasma levels in different phases of activity of coronary atherosclerosis

Protein Z plasma levels in different phases of activity of coronary atherosclerosis

We previously reported that low protein Z plasma levels are associated with acute coronary syndromes (ACS). Aim of the present study was to evaluate protein Z levels in different phases of activity of coronary atherosclerosis. Protein Z plasma levels were measured in 166 (131 male and 35 female) pat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and haemostasis Vol. 3; no. 10; pp. 2254 - 2258
Main Authors: SOFI, F., CESARI, F., VIGIANI, S., FATINI, C., MARCUCCI, R., GIGLIOLI, C., VALENTE, S., ABBATE, R., GENSINI, G. F., FEDI, S.
Format: Journal Article
Language:English
Published: Oxford, UK Blackwell Science Inc 01-10-2005
Subjects:
acute coronary syndromes
Adult
Aged
Aged, 80 and over
Blood Proteins - analysis
Case-Control Studies
Coronary Artery Disease - blood
Coronary Artery Disease - etiology
coronary atherosclerosis
Disease Susceptibility
Female
Humans
Male
Middle Aged
Odds Ratio
protein Z
Risk Factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We previously reported that low protein Z plasma levels are associated with acute coronary syndromes (ACS). Aim of the present study was to evaluate protein Z levels in different phases of activity of coronary atherosclerosis. Protein Z plasma levels were measured in 166 (131 male and 35 female) patients consecutively admitted to the University of Florence with a diagnosis of ACS (group A), 166 (131 male and 35 female) patients selected by age and gender in relation to group A from those with a clinical history of ACS who remained symptom‐ and/or event‐free over the last year before the investigation (group B); and 332 (262 male and 70 female) controls comparable for age and gender with the other two groups. None had liver or renal dysfunction nor showed a positivity for antiphospholipid antibodies or for factor V Leiden mutation. Patients under warfarin therapy were excluded. Mean protein Z plasma levels were found to be significantly (P < 0.0001) lower in group A (1475 ± 684.1 ng mL−1) and group B (1327.6 ± 690.7 ng mL−1) as compared with control group (1650.1 ± 634.5 ng mL−1), while no significant differences existed between the two groups of patients (P = 0.06). A logistic regression analysis, performed after the division of the study population into quartiles of protein Z levels and adjusted for all possible confounders, showed a significant increased risk of ACS for the lowest (<1213 ng mL−1) as compared with the highest quartile of protein Z in both groups of patients [group A odds ratio (OR): 2.7, 95% CI 1.3–5.5, P = 0.007; group B OR: 3.2, 95% CI 1.1–8.9, P = 0.02). In conclusion, these results strengthen our previous data on low protein Z plasma levels in ACS and indicate a possible dose–response effect of decreasing protein Z plasma levels on the coronary atherosclerotic disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1538-7933
1538-7836
1538-7836
DOI:10.1111/j.1538-7836.2005.01536.x